Risus Advisers represents dentists — only dentists — in DSO and private-equity practice transitions. No buyer-side fees. No referral arrangements with acquirers. Flat fees, paid only by you. Founded and run by a practicing DDS.
Request a valuation reviewNo cost, no obligation. We'll tell you if you shouldn't sell.
Most "free" transition help is paid for by the party sitting across the table from you. That doesn't make brokers dishonest — it makes their incentives different from yours.
This isn't scarcity marketing. It's what the transaction data currently shows — every figure below is sourced.
Industry valuation ranges, current vs. the compression expected as the market matures. On a practice doing $400k EBITDA, the gap between a 7× and a 5× outcome is roughly $800,000 — which is why when you go to market matters as much as who you sell to.
Sources. Locations sold, consolidation share and EBITDA ranges: “U.S. dental M&A begins to rebound as practice consolidation advances,” Oral Health Group, 2026, reporting at least 175 locations sold in the first six months of 2026, an industry approximately 35% consolidated (TUSK Practice Sales citing ADA data), current multiples of five to more than nine times EBITDA, and a forecast long-term shift toward four to six times. Recapitalization expectation: TUSK Practice Sales Q2 2026 Dental Market Report, in which 78% of respondents indicated anticipated recapitalizations within a 12- to 36-month window. Ranges are industry-wide and are not a valuation of any individual practice.
We normalize your P&L, calculate defensible adjusted EBITDA, and give you a realistic range — not the inflated number used to win your signature.
Which DSOs actually fit your practice, your staff, and how you want to work afterward. Backed by our independent DSO research.
Headline price is the easy part. We read the earnout mechanics, equity rollover terms, restrictive covenants, and the post-close employment agreement — where most of the real money is won or lost.
You stay in the chair. We handle the analysis, the counters, and coordination with your CPA and attorney through close.
A broker's 6–12% commission on a $2.5M sale is $150,000–$300,000. Our fees don't change with your sale price, and they don't depend on whether you sell at all.
A 30-minute call and a quick read of your P&L and any offer in hand. You'll hear whether to sell now, wait, or not sell.
Normalized P&L, defensible adjusted EBITDA, and a realistic value range in writing.
LOI, earnout, equity rollover, non-compete, and the post-close employment agreement — a written memo plus a call.
Buyer screening, competing offers, and negotiation support through close. Fees already paid are credited.
Founding-client pricing for our first ten engagements.
Risus Advisers was founded by a practicing dentist. That matters for one specific reason: the terms that determine whether you're happy three years after closing aren't financial — they're clinical and operational.
Production quotas. Lab and supply mandates. Who controls your schedule. Whether you can still refer out the cases you don't want. Assistant staffing ratios. Non-competes drawn wide enough to push you out of your own city.
Someone who has never worked a clinical day reads those clauses as boilerplate. They aren't. They're the difference between a good exit and three years you regret.
Blane Jackson, DDS, MBA — 18+ years in practice, licensed in five states, Fellow of the Academy of General Dentistry, MBA with a healthcare concentration. He has built, run and sold dental practices himself.
By you, directly, and only in flat fees: the initial review is free, a valuation report is $750, an offer and contract review is $1,500, and full sell-side representation is $7,500 with earlier fees credited. No percentage of your sale. We accept no buyer-side compensation, no DSO referral fees, and no finder's arrangements.
Yes, and you should know that. Our founder also owns and operates dental practices. Risus Advisers never refers a client to his own entities, never makes an offer on a client's practice, and keeps client information separate from them. If that ever creates a conflict on your deal, we'll say so and step aside.
Yes, and we do. If your EBITDA is depressed by something fixable in 18 months, selling now is the most expensive decision available to you. That advice is worth more than the engagement fee.
No — that's often the best time to bring us in. A signed LOI is not a closed deal, and most of the terms that matter are still negotiable. Send it over.
No. We work alongside them. Your attorney handles legal enforceability; your CPA handles tax structure. We handle valuation, buyer fit, and deal-term strategy — and make sure all three of us are pulling the same direction.
Single-location practices through small groups.
Send your last two years of P&L and any offer you've received. You'll get a realistic valuation range and a plain-English read on the terms — before you're across the table.
Request a valuation reviewConfidential. No cost for the initial review.